The OncomineTM Dx Target Test approved in the United States analyzes 46 target genes, and has been approved as a CDx to determine whether to administer the Food and Drug Administration (FDA)-approved drugs targeting three genes (EGFR, BRAF, and ROS1) among 23 genes related to non-small-cell lung cancer (NSCLC) [23]. The gene discussed is ROS1; the disease is non-small cell lung carcinoma.